Is Humacyte, Inc. (HUMA) a Buy, Sell, or Hold?
Humacyte, Inc.
NASDAQ:HUMA
$0.7072 USD
$0.02 (2.31%)
- Volume
- 7.74M
- Average Volume
- 10.37M
- Market Capitalization
- $118.81M
- P/E Ratio
- -1.20
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $2.84
- Year Low
- $0.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.93
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Laura E. Niklason |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HUMA |
| CUSIP | 44486Q103 |
| CIK | 0001818382 |
| Web | https://www.humacyte.com |
| Phone | 919 313 9633 |
| Currency | USD |
| Employees | 184 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 5.67 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.93 |
| Quick Ratio | 3.32 |
| Cash Ratio | 3.00 |
Sales & Book Value
| Annual Sales | $2.04M |
| Price / Sales | 58.93 |
| Cash Flow | -0.52 |
| Price / Cash Flow | -1.16 |
| Price / Book | 12.04 |
Price Target and Rating
| Average Stock Price Forecast | $5.50 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -87.14% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.26 |
| Trailing P/E Ratio | -1.20 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-40.83M |
| Net Margin | -4840.82% |
| Pretax Margin | -4840.82% |
| Return on Equity | -2781.56% |
| Return on Assets | -88.27% |
Financials Score
| AltmanZ Score | -10.79 |
| Piotroski Score | 1.00 |
| Working Capital | 47.41M |
| Total Assets | 110.56M |
| Ebit | -87.07M |
| Market Cap | 115.38M |
| Total Liabilities | 98.93M |
Poll Results
About Humacyte, Inc. (NASDAQ:HUMA) Stock
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular tr ... auma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
2026-07-14 19:16:11
Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.
2026-07-14 08:00:00
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
2026-06-30 19:02:13
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
2026-06-25 19:15:57
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
2026-06-19 10:30:42
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
2026-06-16 19:00:17
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
2026-06-15 20:22:09
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
2026-06-15 13:01:14
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Frequently Asked Questions
-
What is the current Humacyte, Inc. (HUMA) stock price?
-
Humacyte, Inc.(NASDAQ:HUMA) stock price is $0.7072 in the last trading session. During the trading session, HUMA stock reached the peak price of $2.84 while $0.547 was the lowest point it dropped to. The percentage change in HUMA stock occurred in the recent session was 2.31% while the dollar amount for the price change in HUMA stock was $0.02.
-
HUMA's industry and sector of operation?
-
The NASDAQ listed HUMA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HUMA?
-
Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer & Treasurer
Shamik J. Parikh | Chief Medical Officer
Sabrina Osborne | Chief People Officer
Laura E. Niklason | Founder, President, Chief Executive Officer & Director
Jim Mercadante | Chief Commercial Officer -
How many employees does HUMA have?
-
Number of HUMA employees currently stands at 184. HUMA operates from 2525 East North Carolina Highway 54, Durham, NC 27713, US.
-
Link for HUMA official website?
-
Official Website of HUMA is: https://www.humacyte.com
-
How do I contact HUMA?
-
HUMA could be contacted at phone #919 313 9633 and can also be accessed through its website. HUMA operates from 2525 East North Carolina Highway 54, Durham, NC 27713, US.
-
How many shares of HUMA are traded daily?
-
The average number of HUMA shares traded daily for last 3 months was 10.37M.
-
What is the market cap of HUMA currently?
-
The market value of HUMA currently stands at $118.81M with its latest stock price at $0.7072